Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) EBIT

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) (RVPHW) currently reports a EBIT of $-23T as of June 2026. That compares with $-19M in the prior-year period — down 121974008.5% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s EBIT history and peer comparisons.

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s EBIT decreased from $-19M to $-23T — a 121974008.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s EBIT of $-23T is lower than the Healthcare sector average of $1.9T. That is roughly 1329.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) reported $-23T in EBIT as of June 2026. That compares with $-19M in the prior-year period — down 121974008.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-23T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Reviva Pharmaceuticals Holdings - Warrants (25/12/2025), and consider following RVPHW for alerts when major investors trade the stock.